Oxford BioDynamics Plc has announced the appointment of Dr. Steven Arrivo as Senior Vice President of Business and Corporate Development. Dr. Arrivo brings over 20 years of experience in the industry, with a focus on personalized medicine. He will be responsible for implementing marketing and sales strategies for the recently launched EpiSwitch Prostate Screening (PSE) test, with a specific focus on growing sales in the US market. Dr. Jon Burrows, CEO of Oxford BioDynamics, expressed his confidence in Dr. Arrivo's abilities and stated that his leadership and knowledge will be invaluable in driving the company's commercial efforts.

Oxford BioDynamics is a biotechnology company that develops precision medicine tests based on the EpiSwitch 3D genomics platform. The company's flagship products include the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and the EpiSwitch PSE (Prostate Screening test) blood tests. The CiRT test is a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments, while the PSE test is a blood test that enhances the predictive accuracy of a PSA test for prostate cancer detection.

In addition to the PSE test, Oxford BioDynamics has also launched its first commercial prognostic test, the EpiSwitch CST (Covid Severity Test), and the EpiSwitch Explorer Array Kit, a microarray kit for high-resolution 3D genome profiling and biomarker discovery. The company's product portfolio is based on its proprietary 3D genomic biomarker platform, EpiSwitch, which can be used to develop molecular diagnostic classifiers for various indications.

Oxford BioDynamics has established partnerships with big pharma companies and leading institutions, including Pfizer, Roche, and Mayo Clinic. The company has a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, and bioinformatic tools for 3D genomics. It is headquartered in Oxford, UK, and is listed on AIM of the London Stock Exchange.